View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 29, 2020

Pneumagen reports positive lab data of Covid-19 drug candidates

University of St Andrews spin-out Pneumagen has reported positive findings from three in-vitro studies of Neumifil and other multivalent carbohydrate binding modules (mCBMs) to prevent infection by coronaviruses, including SARS-CoV-2.

University of St Andrews spin-out Pneumagen has reported positive findings from three in-vitro studies of Neumifil and other multivalent carbohydrate binding modules (mCBMs) to prevent infection by coronaviruses, including SARS-CoV-2.

The drug candidates are based on the company’s GlycoTarge platform, which can be used to create glycan targeted mCBMs from bacterial glycosidases.

These mCBMs could help prevent and also treat respiratory tract infections (RTIs) via attachment to epithelial cell surface glycan receptors in the respiratory tract, said Pneumagen.

Neumifil is the company’s lead candidate already being developed as a universal therapy for respiratory tract infections (RTIs), including influenza virus (IFV) and respiratory syncytial virus (RSV).

The drug is designed to mask glycan receptors in airways to prevent the entry of the virus. This mechanism is expected to deliver complete protection from any circulating viral strain.

Pneumagen collaborated with Public Health England’s Porton facility and the University of Glasgow’s MRC Centre for Virus Research to test the mCBMs against coronaviruses by using plaque reduction assays.

Findings showed that the mCBMs could decrease the number of SARS-CoV-2 plaques in plaque reduction assays when used for prevention, as well as treatment of infection.

This is said to build on the company’s previous findings with another clinically relevant coronavirus that causes the common cold, whereby a plaque reduction assay showed antiviral activity with mCBMs.

Pneumagen CEO Douglas Thomson said: “Today’s positive results from in-vitro studies of our mCBMs against coronaviruses show that glycan-binding has the potential to prevent and treat infection.

“This further supports the value of our universal therapeutic modality to block access to lung cells of SARS-CoV-2, as well as other viruses, that causes respiratory tract infections, providing the potential for a pan-viral respiratory product.”

The company aims to rapidly advance drug candidates into clinical testing to prevent and treat Covid-19.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU